Logo image of AKBA

AKEBIA THERAPEUTICS INC (AKBA) Stock Fundamental Analysis

NASDAQ:AKBA - Nasdaq - US00972D1054 - Common Stock - Currency: USD

3.72  -0.04 (-1.06%)

After market: 3.72 0 (0%)

Fundamental Rating

3

Taking everything into account, AKBA scores 3 out of 10 in our fundamental rating. AKBA was compared to 551 industry peers in the Biotechnology industry. AKBA has a bad profitability rating. Also its financial health evaluation is rather negative. AKBA is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

AKBA had negative earnings in the past year.
AKBA had a negative operating cash flow in the past year.
AKBA had negative earnings in each of the past 5 years.
AKBA had a negative operating cash flow in each of the past 5 years.
AKBA Yearly Net Income VS EBIT VS OCF VS FCFAKBA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

AKBA has a better Return On Assets (-14.61%) than 81.13% of its industry peers.
With a Return On Equity value of -184.34%, AKBA is not doing good in the industry: 65.52% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -14.61%
ROE -184.34%
ROIC N/A
ROA(3y)-26.46%
ROA(5y)-38.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AKBA Yearly ROA, ROE, ROICAKBA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

AKBA's Gross Margin of 82.92% is amongst the best of the industry. AKBA outperforms 86.93% of its industry peers.
In the last couple of years the Gross Margin of AKBA has grown nicely.
The Profit Margin and Operating Margin are not available for AKBA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.75%
GM growth 5Y4.73%
AKBA Yearly Profit, Operating, Gross MarginsAKBA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

2

2. Health

2.1 Basic Checks

AKBA does not have a ROIC to compare to the WACC, probably because it is not profitable.
AKBA has more shares outstanding than it did 1 year ago.
AKBA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, AKBA has a worse debt to assets ratio.
AKBA Yearly Shares OutstandingAKBA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
AKBA Yearly Total Debt VS Total AssetsAKBA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

AKBA has an Altman-Z score of -4.64. This is a bad value and indicates that AKBA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of AKBA (-4.64) is comparable to the rest of the industry.
A Debt/Equity ratio of 1.89 is on the high side and indicates that AKBA has dependencies on debt financing.
The Debt to Equity ratio of AKBA (1.89) is worse than 80.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.89
Debt/FCF N/A
Altman-Z -4.64
ROIC/WACCN/A
WACC11.06%
AKBA Yearly LT Debt VS Equity VS FCFAKBA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

AKBA has a Current Ratio of 2.23. This indicates that AKBA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.23, AKBA is doing worse than 73.32% of the companies in the same industry.
AKBA has a Quick Ratio of 2.02. This indicates that AKBA is financially healthy and has no problem in meeting its short term obligations.
AKBA has a Quick ratio of 2.02. This is in the lower half of the industry: AKBA underperforms 74.05% of its industry peers.
Industry RankSector Rank
Current Ratio 2.23
Quick Ratio 2.02
AKBA Yearly Current Assets VS Current LiabilitesAKBA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 8.70% over the past year.
Looking at the last year, AKBA shows a decrease in Revenue. The Revenue has decreased by -1.23% in the last year.
The Revenue for AKBA have been decreasing by -13.72% on average. This is quite bad
EPS 1Y (TTM)8.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%133.33%
Revenue 1Y (TTM)-1.23%
Revenue growth 3Y-8.88%
Revenue growth 5Y-13.72%
Sales Q2Q%75.84%

3.2 Future

AKBA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.25% yearly.
AKBA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.28% yearly.
EPS Next Y80.22%
EPS Next 2Y49.5%
EPS Next 3Y33.34%
EPS Next 5Y29.25%
Revenue Next Year33.03%
Revenue Next 2Y38.35%
Revenue Next 3Y26.77%
Revenue Next 5Y26.28%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AKBA Yearly Revenue VS EstimatesAKBA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
AKBA Yearly EPS VS EstimatesAKBA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -2 -4

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AKBA. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 47.99, the valuation of AKBA can be described as expensive.
Based on the Price/Forward Earnings ratio, AKBA is valued cheaper than 89.47% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.28, AKBA is valued a bit more expensive.
Industry RankSector Rank
PE N/A
Fwd PE 47.99
AKBA Price Earnings VS Forward Price EarningsAKBA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AKBA is valued cheaply inside the industry as 91.29% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 90.08
AKBA Per share dataAKBA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

AKBA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AKBA's earnings are expected to grow with 33.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.5%
EPS Next 3Y33.34%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AKBA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKEBIA THERAPEUTICS INC

NASDAQ:AKBA (8/5/2025, 8:00:00 PM)

After market: 3.72 0 (0%)

3.72

-0.04 (-1.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners35.84%
Inst Owner Change-2.75%
Ins Owners3.51%
Ins Owner Change1.02%
Market Cap977.02M
Analysts87.27
Price Target7.55 (102.96%)
Short Float %10.35%
Short Ratio5.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)71.41%
Min EPS beat(2)-22.55%
Max EPS beat(2)165.36%
EPS beat(4)2
Avg EPS beat(4)28.62%
Min EPS beat(4)-54.81%
Max EPS beat(4)165.36%
EPS beat(8)4
Avg EPS beat(8)8.98%
EPS beat(12)7
Avg EPS beat(12)20.67%
EPS beat(16)7
Avg EPS beat(16)9.15%
Revenue beat(2)2
Avg Revenue beat(2)23.65%
Min Revenue beat(2)22.05%
Max Revenue beat(2)25.24%
Revenue beat(4)2
Avg Revenue beat(4)4.07%
Min Revenue beat(4)-17.55%
Max Revenue beat(4)25.24%
Revenue beat(8)2
Avg Revenue beat(8)-4.48%
Revenue beat(12)5
Avg Revenue beat(12)9.4%
Revenue beat(16)7
Avg Revenue beat(16)9.7%
PT rev (1m)0%
PT rev (3m)0.34%
EPS NQ rev (1m)0%
EPS NQ rev (3m)63.16%
EPS NY rev (1m)0%
EPS NY rev (3m)66.75%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)6.66%
Revenue NY rev (1m)0.85%
Revenue NY rev (3m)4.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 47.99
P/S 5.28
P/FCF N/A
P/OCF N/A
P/B 39.75
P/tB N/A
EV/EBITDA 90.08
EPS(TTM)-0.21
EYN/A
EPS(NY)0.08
Fwd EY2.08%
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS0.7
BVpS0.09
TBVpS-0.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.61%
ROE -184.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.92%
FCFM N/A
ROA(3y)-26.46%
ROA(5y)-38.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.75%
GM growth 5Y4.73%
F-Score3
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 1.89
Debt/FCF N/A
Debt/EBITDA 4.55
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.23
Quick Ratio 2.02
Altman-Z -4.64
F-Score3
WACC11.06%
ROIC/WACCN/A
Cap/Depr(3y)0.13%
Cap/Depr(5y)0.3%
Cap/Sales(3y)0.02%
Cap/Sales(5y)0.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%133.33%
EPS Next Y80.22%
EPS Next 2Y49.5%
EPS Next 3Y33.34%
EPS Next 5Y29.25%
Revenue 1Y (TTM)-1.23%
Revenue growth 3Y-8.88%
Revenue growth 5Y-13.72%
Sales Q2Q%75.84%
Revenue Next Year33.03%
Revenue Next 2Y38.35%
Revenue Next 3Y26.77%
Revenue Next 5Y26.28%
EBIT growth 1Y47.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.6%
OCF growth 3YN/A
OCF growth 5YN/A